372 related articles for article (PubMed ID: 18249108)
1. Polo and Aurora kinases: lessons derived from chemical biology.
Taylor S; Peters JM
Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
[TBL] [Abstract][Full Text] [Related]
2. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
[TBL] [Abstract][Full Text] [Related]
3. PLK1 inhibitors: setting the mitotic death trap.
Plyte S; Musacchio A
Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase controls vertebrate spindle elongation and cytokinesis.
Brennan IM; Peters U; Kapoor TM; Straight AF
PLoS One; 2007 May; 2(5):e409. PubMed ID: 17476331
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Plk1 induces mitotic infidelity and embryonic growth defects in developing zebrafish embryos.
Jeong K; Jeong JY; Lee HO; Choi E; Lee H
Dev Biol; 2010 Sep; 345(1):34-48. PubMed ID: 20553902
[TBL] [Abstract][Full Text] [Related]
6. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1.
Petronczki M; Lénárt P; Peters JM
Dev Cell; 2008 May; 14(5):646-59. PubMed ID: 18477449
[TBL] [Abstract][Full Text] [Related]
7. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
[TBL] [Abstract][Full Text] [Related]
8. Integrated computational model of cell cycle and checkpoint reveals different essential roles of Aurora-A and Plk1 in mitotic entry.
Zou J; Luo SD; Wei YQ; Yang SY
Mol Biosyst; 2011 Jan; 7(1):169-79. PubMed ID: 20978655
[TBL] [Abstract][Full Text] [Related]
9. Targeting polo-like kinase: learning too little too late?
Olmos D; Swanton C; de Bono J
J Clin Oncol; 2008 Dec; 26(34):5497-9. PubMed ID: 18955441
[No Abstract] [Full Text] [Related]
10. Aurora-A and hBora join the game of Polo.
Macurek L; Lindqvist A; Medema RH
Cancer Res; 2009 Jun; 69(11):4555-8. PubMed ID: 19487276
[TBL] [Abstract][Full Text] [Related]
11. Pinning down the polo-box domain.
Lee KS; Idle JR
Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
Chopra P; Sethi G; Dastidar SG; Ray A
Expert Opin Investig Drugs; 2010 Jan; 19(1):27-43. PubMed ID: 20001553
[TBL] [Abstract][Full Text] [Related]
15. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
16. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase (Plk) 1 as a target for prostate cancer management.
Reagan-Shaw S; Ahmad N
IUBMB Life; 2005 Oct; 57(10):677-82. PubMed ID: 16223707
[TBL] [Abstract][Full Text] [Related]
18. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
Rheault TR; Donaldson KH; Badiang-Alberti JG; Davis-Ward RG; Andrews CW; Bambal R; Jackson JR; Cheung M
Bioorg Med Chem Lett; 2010 Aug; 20(15):4587-92. PubMed ID: 20594842
[TBL] [Abstract][Full Text] [Related]
19. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.
Ditchfield C; Johnson VL; Tighe A; Ellston R; Haworth C; Johnson T; Mortlock A; Keen N; Taylor SS
J Cell Biol; 2003 Apr; 161(2):267-80. PubMed ID: 12719470
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
